Ulf Elbelt1, Alessia Trovato, Michael Kloth, Enno Gentz, Reinhard Finke, Joachim Spranger, David Galas, Susanne Weber, Cristina Wolf, Katharina König, Wiebke Arlt, Reinhard Büttner, Patrick May, Bruno Allolio, Jochen G Schneider. 1. Department of Endocrinology, Diabetes, and Nutrition (U.E., A.T., J.S.), Department of Hepatology and Gastroenterology (E.G.), Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany; Institute of Pathology (M.K., K.K., R.B.), University of Cologne, 50937 Cologne, Germany; Praxisgemeinschaft an der Kaisereiche (R.F.), 12159 Berlin, Germany; Luxembourg Centre for Systems Biomedicine (D.G., C.W., P.M., J.G.S.), University of Luxembourg, 4362 Luxembourg, Luxembourg; Pacific Northwest Diabetes Research Institute (D.G.), Seattle, Washington 98122; Department of Internal Medicine II (S.W., C.W.), Saarland University Medical Center, 66421 Homburg/Saar, Germany; Centre for Endocrinology, Diabetes, and Metabolism (W.A.), School of Clinical and Experimental Medicine, University of Birmingham, Birmingham B15 2TT, United Kingdom; Family Genomes Group (P.M.), Institute for Systems Biology, Seattle, Washington 98109; and Department of Internal Medicine I (B.A.), Endocrine and Diabetes Unit, University Hospital Würzburg, 97080 Würzburg, Germany.
Abstract
CONTEXT: Primary macronodular adrenal hyperplasia (PMAH) is a rare cause of Cushing's syndrome, which may present in the context of different familial multitumor syndromes. Heterozygous inactivating germline mutations of armadillo repeat containing 5 (ARMC5) have very recently been described as cause for sporadic PMAH. Whether this genetic condition also causes familial PMAH in association with other neoplasias is unclear. OBJECTIVE: The aim of the present study was to delineate the molecular cause in a large family with PMAH and other neoplasias. PATIENTS AND METHODS: Whole-genome sequencing and comprehensive clinical and biochemical phenotyping was performed in members of a PMAH affected family. Nodules derived from adrenal surgery and pancreatic and meningeal tumor tissue were analyzed for accompanying somatic mutations in the identified target genes. RESULTS: PMAH presenting either as overt or subclinical Cushing's syndrome was accompanied by a heterozygous germline mutation in ARMC5 (p.A110fs*9) located on chromosome 16. Analysis of tumor tissue showed different somatic ARMC5 mutations in adrenal nodules supporting a second hit hypothesis with inactivation of a tumor suppressor gene. A damaging somatic ARMC5 mutation was also found in a concomitant meningioma (p.R502fs) but not in a pancreatic tumor, suggesting biallelic inactivation of ARMC5 as causal also for the intracranial meningioma. CONCLUSIONS: Our analysis further confirms inherited inactivating ARMC5 mutations as a cause of familial PMAH and suggests an additional role for the development of concomitant intracranial meningiomas.
CONTEXT: Primary macronodular adrenal hyperplasia (PMAH) is a rare cause of Cushing's syndrome, which may present in the context of different familial multitumor syndromes. Heterozygous inactivating germline mutations of armadillo repeat containing 5 (ARMC5) have very recently been described as cause for sporadic PMAH. Whether this genetic condition also causes familial PMAH in association with other neoplasias is unclear. OBJECTIVE: The aim of the present study was to delineate the molecular cause in a large family with PMAH and other neoplasias. PATIENTS AND METHODS: Whole-genome sequencing and comprehensive clinical and biochemical phenotyping was performed in members of a PMAH affected family. Nodules derived from adrenal surgery and pancreatic and meningeal tumor tissue were analyzed for accompanying somatic mutations in the identified target genes. RESULTS: PMAH presenting either as overt or subclinical Cushing's syndrome was accompanied by a heterozygous germline mutation in ARMC5 (p.A110fs*9) located on chromosome 16. Analysis of tumor tissue showed different somatic ARMC5 mutations in adrenal nodules supporting a second hit hypothesis with inactivation of a tumor suppressor gene. A damaging somatic ARMC5 mutation was also found in a concomitant meningioma (p.R502fs) but not in a pancreatic tumor, suggesting biallelic inactivation of ARMC5 as causal also for the intracranial meningioma. CONCLUSIONS: Our analysis further confirms inherited inactivating ARMC5 mutations as a cause of familial PMAH and suggests an additional role for the development of concomitant intracranial meningiomas.
Authors: H S Willenberg; C A Stratakis; C Marx; M Ehrhart-Bornstein; G P Chrousos; S R Bornstein Journal: N Engl J Med Date: 1998-07-02 Impact factor: 91.245
Authors: C Nies; D K Bartsch; K Ehlenz; A Wild; P Langer; S Fleischhacker; M Rothmund Journal: Exp Clin Endocrinol Diabetes Date: 2002-09 Impact factor: 2.949
Authors: Hui-Pin Hsiao; Lawrence S Kirschner; Isabelle Bourdeau; Margaret F Keil; Sosipatros A Boikos; Somya Verma; Audrey J Robinson-White; Maria Nesterova; André Lacroix; Constantine A Stratakis Journal: J Clin Endocrinol Metab Date: 2009-06-09 Impact factor: 5.958
Authors: Miriam J Smith; James O'Sullivan; Sanjeev S Bhaskar; Kristen D Hadfield; Gemma Poke; John Caird; Saba Sharif; Diana Eccles; David Fitzpatrick; Daniel Rawluk; Daniel du Plessis; William G Newman; D Gareth Evans Journal: Nat Genet Date: 2013-02-03 Impact factor: 38.330
Authors: Mihail Zilbermint; Paraskevi Xekouki; Fabio R Faucz; Annabel Berthon; Alexandra Gkourogianni; Marie Helene Schernthaner-Reiter; Maria Batsis; Ninet Sinaii; Martha M Quezado; Maria Merino; Aaron Hodes; Smita B Abraham; Rossella Libé; Guillaume Assié; Stéphanie Espiard; Ludivine Drougat; Bruno Ragazzon; Adam Davis; Samson Y Gebreab; Ryan Neff; Electron Kebebew; Jérôme Bertherat; Maya B Lodish; Constantine A Stratakis Journal: J Clin Endocrinol Metab Date: 2015-03-30 Impact factor: 5.958
Authors: Crystal D C Kamilaris; Fady Hannah-Shmouni; Constantine A Stratakis Journal: Best Pract Res Clin Endocrinol Metab Date: 2020-05-23 Impact factor: 4.690
Authors: Svetozar S Damjanovic; Jadranka A Antic; Valentina I Elezovic-Kovacevic; Dusko M Dundjerovic; Ivana T Milicevic; Bojana B Beleslin-Cokic; Bojana B Ilic; Gordana S Rodic; Annabel Berthon; Andrea Gutierrez Maria; Fabio R Faucz; Constantine A Stratakis Journal: J Clin Endocrinol Metab Date: 2020-12-01 Impact factor: 5.958
Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin Journal: J Clin Endocrinol Metab Date: 2015-07-29 Impact factor: 5.958
Authors: N M Albiger; D Regazzo; B Rubin; A M Ferrara; S Rizzati; E Taschin; F Ceccato; G Arnaldi; F Pecori Giraldi; A Stigliano; L Cerquetti; F Grimaldi; E De Menis; M Boscaro; M Iacobone; G Occhi; C Scaroni Journal: Endocrine Date: 2016-04-19 Impact factor: 3.633